Vanguard Group’s Sagimet Biosciences SGMT Stock Holding History

Vanguard Group’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$7.46M	Buy	1,259,550 +56,319	+5%	+$405K	﹤0.01%	3103
2025 Q3	$8.25M	Buy	1,203,231 +49,375	+4%	+$400K	﹤0.01%	3073
2025 Q2	$8.79M	Hold	1,153,856	–	–	﹤0.01%	2971
2025 Q1	$3.76M	Buy	1,153,856 +22,729	+2%	+$95.3K	﹤0.01%	3277
2024 Q4	$5.09M	Buy	1,131,127 +83,587	+8%	+$423K	﹤0.01%	3264
2024 Q3	$2.9M	Sell	1,047,540 -26,598	-2%	-$82K	﹤0.01%	3446
2024 Q2	$3.67M	Sell	1,074,138 -65,269	-6%	-$299K	﹤0.01%	3381
2024 Q1	$6.18M	Buy	1,139,407 +894,319	+365%	+$6.42M	﹤0.01%	3213
2023 Q4	$1.33M	Sell	245,088 -930	-0.4%	-$4.39K	﹤0.01%	3740
2023 Q3	$2.16M	Buy	+246,018	New	+$3.28M	﹤0.01%	3555

Other funds holding SGMT

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group's SGMT Position: Q4 2025 in Review

Vanguard Group increased its Sagimet Biosciences (SGMT) stake by 4.7% in Q4 2025, buying an estimated $405K and bringing the position to 1,259,550 shares worth $7.46M. The position accounts for ﹤0.01% of the portfolio, ranked #3103.

Vanguard Group first reported a position in SGMT in Q3 2023 and has held it in 10 quarters since. The position peaked at $8.79M in Q2 2025. 86 funds tracked by Wall St. Rank hold SGMT as of Q4 2025.

Vanguard Group held 1,259,550 shares of Sagimet Biosciences worth $7.46M as of Q4 2025.
Vanguard Group bought 56,319 Sagimet Biosciences shares in Q4 2025, an estimated $405K.
Sagimet Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3103 holding.
Vanguard Group first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 10 quarters since.
Vanguard Group's Sagimet Biosciences position peaked at $8.79M in Q2 2025.
86 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.